Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis

Abstract

Background

Vitamin D is important for bone health and immune regulation, and has been shown to be low in multiple sclerosis (MS). We sought to determine the effect of over the counter low dose cholecalciferol (LDC) and high dose ergocalciferol (HDE) on the vitamin D levels in MS patients.

Methods

We retrospectively evaluated serum 25-hydroxy-vitamin D [25(OH)D] levels of 199 patients (CIS, n = 32; RRMS, n = 115; PPMS, n = 10; SPMS, n = 16; Transverse Myelitis (TM), n = 9; other neurological diseases, n = 16) attending our clinic between 2004 and 2008. We examined the change in 25(OH)D levels in 40 MS patients who took either LDC (≤800 IU/day) or HDE (50,000 IU/day for 7-10 days, followed by 50,000 IU weekly or biweekly).

Results

The average 25(OH)D level was 71 ± 39 nmol/L (Mean ± SD), and 167(84%) patients had insufficient levels (≤100 nmol/L) of 25(OH)D. The patients supplemented with LDC did not have a significant increase in their 25(OH)D levels. However, 25(OH)D levels increased by 42 nmol/L (P = 0.01) in the patients originally taking LDC and then prescribed HDE. Optimal levels (≥100 nmol/L) were only achieved in less than 40% of patients.

Conclusions

We conclude that large numbers of patients with MS and TM in our cohort are deficient in vitamin D. HDE significantly elevated 25(OH)D levels in MS patients and was more effective at increasing 25(OH)D levels than LDC. Prospective studies are required to determine appropriate dosing regimen to achieve optimal levels in the majority of MS patients and to ascertain the safety, immunological response, and ultimately the clinical efficacy of vitamin D replacement therapy.

Keywords

25-hydroxy vitamin D cholecalciferol demyelinating diseases ergocalciferol MS vitamin D deficiency

Get full access to this article

View all access options for this article.

References

1 Cosman F Nieves J Komar L . Fracture history and bone loss in patients with MS. Neurology 1998; 51: 1161–1165.

2 Sato K Suematsu A Okamoto K . Th17 functions as an osteoclastogenic helper T Cell subset that links T Cell activation and bone destruction. J Exp Med 2006; 203: 2673–2682.

3 Arnson Y Amital H Shoenfeld Y . Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137–1142.

4 Gauzzi MC Purificato C Donato K . Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 2005; 174: 270–276.

5 Adorini L . Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115–124.

6 Lyakh LA Sanford M Chekol S Young HA Roberts AB . TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J Immunol 2005; 174: 2061–2070.

7 Subramaniam N Leong GM Cock TA . Cross-Talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001; 276: 15741–15746.

8 Aschenbrenner JK Sollinger HW Becker BN Hullett DA . 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171–175.

9 Tone Y Furuuchi K Kojima Y Tykocinski ML Greene MI Tone M . Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008; 9: 194–202.

10.

10 Munger KL Levin LI Hollis BW Howard NS Ascherio A . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.

11.

11 Munger KL Zhang SM O’Reilly E . Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60–65.

12.

12 Goldberg P Fleming MC Picard EH . Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986; 21: 193–200.

13.

13 Wingerchuk DM Lesaux J Rice GP Kremenchutzky M Ebers GC . A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1294–1296.

14.

14 Polman CH Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

15.

15 Transverse Myelitis Consortium Working Group . Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499–505.

16.

16 Holick MF . Vitamin D deficiency. N Engl J Med 2007; 357: 266–281.

17.

17 Holick MF . The vitamin D epidemic and its health consequences. J Nutr 2005; 135: 2739S–2748S.

18.

18 Zadshir A; Tareen N; Pan D; Norris K; Martins D; . The prevalence of hypovitaminosis D among us adults: data from the NHANES III. Ethn Dis 2005; 15: S5–97–101.

19.

19 Chen TC Chimeh F Lu Z . Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007; 460: 213–217.

20.

20 Nieves J Cosman F Herbert J Shen V Lindsay R . High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687–1692.

21.

21 Holick MF Biancuzzo RM Chen TC . Vitamin D2 is as effective as Vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677–681.

22.

22 Jodie MB; Samantha K; Reinhold V; . Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. American Academy of Neurology 2008; 70(Suppl. 1): 105.

23.

23 Kimball SM Ursell MR O’Connor P Vieth R . Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645–651.

24.

24 Hollis BW . Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317–322.

25.

25 Vieth R . Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004; 89–90: 575–579.

26.

26 Tzartos JS Friese MA Craner MJ . Interleukin-17 production in central nervous system-infiltrating T Cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146–155.

27.

27 Kebir H Kreymborg K Ifergan I . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173–1175.